Related Experiment Video

Updated: Mar 29, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

To determine the frequency of Factor V Leiden in cases of Deep Vein Thrombosis and Healthy controls

Anjum Saeed1, Sumreen2, Muhammad Ali Kashif3

  • 1Dr. Anjum Saeed, M.Phil Haematology, Frontier Medical College Abbotabad, Pakistan. Abbotabad - Pakistan.

Pakistan Journal of Medical Sciences
|December 10, 2015
PubMed

Insights

Factor V Leiden (FVL) mutation is significantly more common in Deep Vein Thrombosis (DVT) patients (13%) than in healthy individuals (2%). This finding highlights a strong association between FVL and DVT risk.

Area of Science:

  • Genetics
  • Hematology
  • Medical Diagnostics

Background:

  • Deep Vein Thrombosis (DVT) is a serious condition often linked to genetic predispositions.
  • Factor V Leiden (FVL) is a common inherited thrombophilia that increases the risk of blood clots.

Purpose of the Study:

  • To investigate the prevalence of the Factor V Leiden mutation in patients diagnosed with Deep Vein Thrombosis.
  • To compare the frequency of Factor V Leiden in DVT patients versus healthy controls.

Main Methods:

  • A case-control study involving 100 DVT patients and 100 healthy controls.
  • DNA extraction from blood samples followed by Polymerase Chain Reaction (PCR) and Amplification Refractory Mutation System (ARMS) to detect the FVL mutation.
  • Statistical analysis using SPSS version 17.

Main Results:

  • The frequency of Factor V Leiden was 13% in the DVT patient group and 2% in the healthy control group.
  • A statistically significant association was observed between Factor V Leiden and DVT (Odds Ratio = 7.32, P = 0.003).

Conclusions:

  • Factor V Leiden is highly prevalent in patients with Deep Vein Thrombosis.
  • The study confirms a strong association between Factor V Leiden mutation and the occurrence of DVT.
Abstract

Keywords:
Deep vein thrombosisFactor V LeidenVenous thromboembolism

More Related Videos

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.1K
Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis06:45

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

16.9K

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
434
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
681
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
465
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K